Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y
Abstract
The potential for influenza A virus (IAV) to cause pandemics makes understanding evolutionary mechanisms that impact drug resistance critical for developing surveillance and treatment strategies. Oseltamivir is the most widely used therapeutic strategy to treat IAV infections, but mutations in IAV can lead to drug resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 23, 2022
- Source ID
- 10.1128/jvi.01982-21
Entities
People
- Celia A. Schiffer
- Daniel Bolon
- Jeffrey D. Jensen
- Jennifer P Wang
- Li Jiang
- Mohan Somasundaran
- Neha Samant
- Ping Liu
- Robert W. Finberg
- Timothy F. Kowalik
- Wayne A Marasco
Organizations
- Arizona State University
- Dana–Farber Cancer Institute
- Office of the Secretary of Defense
- University of Massachusetts Medical School